Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pimurutamab - Shanghai Henlius Biotech

Next Previous
Search
Drug Profile

Pimurutamab - Shanghai Henlius Biotech

Alternative Names: Cetuximab biobetter - Henlix Biotech; HLX 07; Recombinant humanized anti-EGFR monoclonal antibody - Shanghai Henlius Biotech

Latest Information Update: 12 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Henlius Biotech
  • Developer Shanghai Henlius Biotech; Wuhan Union Hospital
  • Class Antineoplastics; Biobetters; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Rectal cancer; Squamous cell cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 19 Jul 2024 Phase-II clinical trials in Rectal cancer (Late-stage disease, Combination therapy) in China (Parenteral) (NCT06542588)
  • 05 Dec 2023 Efficacy and adverse events data from a phase II trial in squamous Non-small-cell Lung Cancer released by Shanghai Henlius Biotech
  • 05 Dec 2023 Efficacy and adverse events data from a phase-II clinical trials in Squamous cell cancer released by Shanghai Henlius Biotech

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top